Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

This study has been completed.
Microgen Scientific Industrial Company for Immunobiological Medicines
Institute of Experimental Medicine, Russia
Information provided by (Responsible Party):
PATH Identifier:
First received: October 26, 2012
Last updated: June 27, 2013
Last verified: March 2013